Operations for lymphedema.
Explore the source record for details and available documents.
Feasibility Studies↗
Biomedical subjects
R Beltramino
Publications and source records attributed to R Beltramino.
An open-label, randomized multicenter study comparing the efficacy and safety of Cyclo 3 Fort versus hydroxyethyl rutoside in chronic venous lymphatic insufficiency.
The present study was designed to compare the safety and efficacy of a combination of Ruscus aculeatus, hesperidin methyl chalcone, and ascorbic acid (Cyclo 3 Fort) versus that of hydroxyethyl rutoside in treatment of chronic venous lymphatic insufficiency. This open-label, randomized multicenter study was conducted on outpatients treated for 90 days. The patients were from three different regions of Argentina. Eighty patients, men and women, 30 to 70 years of age, with symptoms of chronic venous lymphatic insufficiency, ie, heavy, tired, swollen, or painful legs, were enrolled and assigned to two groups: one group treated with Cyclo 3 Fort, the other with rutoside. The symptoms were assessed at baseline, and after 30, 60, and 90 days. The patient was asked to assess subjective symptoms, and the physician measured the size of the affected limbs. The efficacy was rated on a 3-point scale and safety was evaluated by the number of side effects. The results show that when all patients were comparable at baseline, after 90 days, patients treated with Cyclo 3 Fort reported more rapid and complete regression of symptoms than those in the rutoside group, a statistically significant difference (p < 0.01). Likewise, a significant reduction in affected limb size was observed in both groups but persisted after 90 days in the Cyclo 3 Fort group only (p < 0.01). Cyclo 3 Fort was safe and more effective than rutoside in the treatment of venous lymphatic insufficiency, and the Cyclo 3 Fort efficacy is probably associated with its unique mechanism of action.
Adult↗
An open-label, randomised multicentre study comparing the efficacy and safety of CYCLO 3 FORT versus hydroxyethyl rutoside in chronic venous lymphatic insufficiency.
BACKGROUND: The present study was designed to compare the safety and efficacy of a combination of Ruscus aculeatus, hesperidin methyl chalcone and ascorbic acid (CYCLO 3 FORT) versus that of hydroxyethyl rutoside in the treatment of chronic venous lymphatic insufficiency. METHODS: This open-label, randomised multicentre study was conducted on outpatients treated for 90 days. The patients were from three different regions of Argentina. Eighty patients, men and women, 30 to 70 years of age, with symptoms of chronic venous lymphatic insufficiency, i.e. heavy, tired, swollen, or painful legs were enrolled and assigned to two groups: one group treated with CYCLO 3 FORT, the other with rutoside. The symptoms were assessed at baseline, and after 30, 60, and 90 days. The patient himself was asked to assess subjective symptoms, the physician measured the size of the affected limbs. The efficacy was rated on a 3-point scale and safety was evaluated by the number of side effects. RESULTS: The result data show that when all patients were comparable at baseline, after 90 days, those treated with CYCLO 3 FORT reported more rapid and more complete regression of symptoms than those in the rutoside group, a statistically significant difference (p<0.01). Likewise, a significant reduction in affected limb size was observed in both groups but persisted after 90 days in the CYCLO 3 FORT group only (p<0.01). CONCLUSIONS: As a conclusion : CYCLO 3 FORT was safe and more effective than rutoside in the treatment of venous lymphatic insufficiency. And the CYCLO 3 FORT efficacy is probably associated with its unique mechanism of action.
Adult↗
[Congenital Chagas disease in the city of Santa Fé. Diagnosis and treatment].
We studied 6123 pregnant women and their 341 newborn (NB), from Santa Fe city, by the following serological tests for chagasic infection: Direct Agglutination with and without 2-mercaptoethanol, Indirect Hemagglutination and Indirect Immunofluorescence test, and by identification of parasites by Fresh drops, Strout and/or by Xenodiagnosis. The prevalence of seropositivity found in pregnant women was of 14.62% with a 73% of migratory history. The parasitological studies yielded 9/341 incidence of transplacentary infection. Clinical examinations were made in the infected newborn (NB). They were treated with Benznidazol or Nifurtimox, and post-treatment evolution was evaluated. We registered connatal infection in twin-brothers. Brothers/sisters (siblings) of infected NB were also studied. Some of them were seropositive and the others seronegative. Results here obtained show that this way of transmission is important, and should be considered even in low endemicity areas. The parasitological assays proved to be decisive for the NB infection diagnosis (Table 1). The serological assays enabled us to follow the non-infected NB up to their negativization. A 6 month follow-up is recommended. It is impossible to define only one clinical outline because both symptomatic and asymptomatic infected NB may be found with gestational age at term and pre-term and when born with a weight above or below 2000 g. We obtained parasitological and serological negativization in all cases. The chagasic pregnant woman does not necessarily transmit the infection to all her descendents. Only 2.64% are infected. It is possible to systematize the diagnosis without extra resources beyond the usual ones.
Animals↗
Scintigraphic documentation of systemic-portal shunting.
Two unusual cases of iliac vein thrombosis are presented. They were studied with radionuclide venography of the left lower-extremity in which one of the collateral channels was the inferior mesenteric vein and showed the entire liver and lungs simultaneously. This vein does not appear to have been clearly identified with radioisotopic techniques previously. Using the anterior projection over the lungs and liver, ratios of liver to lungs, liver to (liver + lungs), right lung to (liver + lungs) and left lungs to (liver + lungs) were calculated. In patient 1, the shunted tracer represented 82% of the total activity and in patient 2 it was 21.5%.
Collateral Circulation↗